Boston Partners
CPRX

Boston Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Boston Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.4M Buy
1,711,573
+480,201
+39% +$11.4M 0.04% 277
2025
Q4 		$28.5M Sell
1,231,372
-59,687
-5% -$1.33M 0.03% 333
2025
Q3 		$25.6M Buy
1,291,059
+8,337
+0.6% +$171K 0.03% 348
2025
Q2 		$27.9M Buy
1,282,722
+7,397
+0.6% +$175K 0.03% 315
2025
Q1 		$30.6M Sell
1,275,325
-16,543
-1% -$373K 0.04% 275
2024
Q4 		$27.3M Buy
1,291,868
+16,601
+1% +$357K 0.03% 294
2024
Q3 		$25.6M Sell
1,275,267
-131,113
-9% -$2.43M 0.03% 303
2024
Q2 		$22M Sell
1,406,380
-100,550
-7% -$1.57M 0.03% 316
2024
Q1 		$23.8M Sell
1,506,930
-34,730
-2% -$523K 0.03% 304
2023
Q4 		$25.6M Buy
1,541,660
+1,396,930
+965% +$19.1M 0.03% 300
2023
Q3 		$1.69M Hold
144,730
– – ﹤0.01% 507
2023
Q2 		$1.95M Hold
144,730
– – ﹤0.01% 482
2023
Q1 		$2.4M Hold
144,730
– – ﹤0.01% 450
2022
Q4 		$2.69M Buy
144,730
+3,351
+2% +$51.6K ﹤0.01% 431
2022
Q3 		$1.81M Buy
141,379
+2,821
+2% +$33.4K ﹤0.01% 456
2022
Q2 		$971K Buy
138,558
+62,812
+83% +$461K ﹤0.01% 514
2022
Q1 		$628K Buy
+75,746
New +$536K ﹤0.01% 603

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Boston Partners's CPRX Position: Q1 2026 in Review

Boston Partners increased its Catalyst Pharmaceutical (CPRX) stake by 39% in Q1 2026, buying an estimated $11.4M and bringing the position to 1,711,573 shares worth $42.4M. The position accounts for 0.04% of the portfolio, ranked #277.

Boston Partners first reported a position in CPRX in Q1 2022 and has held it in 17 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Boston Partners held 1,711,573 shares of Catalyst Pharmaceutical worth $42.4M as of Q1 2026.
  • Boston Partners bought 480,201 Catalyst Pharmaceutical shares in Q1 2026, an estimated $11.4M.
  • Catalyst Pharmaceutical made up 0.04% of Boston Partners's portfolio in Q1 2026, its #277 holding.
  • Boston Partners first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 17 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Boston Partners's 13F filing for Q1 2026, filed 11 May 2026.